10-Q: DiaMedica Therapeutics Faces Financial Hurdles Amidst Clinical Trials

DiaMedica Therapeutics Inc. reported continued operating losses and a significant cash burn in its Q3 2026 filing, raising concerns about its going concern status, even as it advances its DM199 clinical programs.

Summary

• DiaMedica Therapeutics Inc. filed its Q3 2026 report, detailing its financial condition and operational progress.
• The company continues to incur substantial operating losses, with a net loss of $31.5 million for the nine months ended September 30, 2026.
• As of September 30, 2026, the company had $34.9 million in cash, cash equivalents, and marketable securities, with a working capital of $28.0 million.
• Significant cash burn is evident, with $26.0 million used in operating activities for the nine months ended September 30, 2026.
• The company faces substantial doubt regarding its ability to continue as a going concern, necessitating significant additional capital.
• Clinical development of DM199 for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS) is ongoing.
• Enrollment in the Phase 2/3 ReMEDy2 trial for AIS has reached 200 participants, with interim analysis results expected by Q1 2027.
• The company is also advancing its PE/FGR program, with initial enrollment in Part 1b and Part 2 expected by the end of 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued operating losses, significant cash burn, and substantial doubt about its ability to continue as a going concern, despite ongoing clinical trial progress.

Positives

• Enrollment of the 200th participant in the ReMEDy2 trial for AIS was announced in October 2026.
• Interim results from the PE/FGR Phase 2 IST demonstrated DM199 is safe and well-tolerated with clinically-relevant pharmacodynamic activity.
• DM199 showed sustained reductions in maternal blood pressure in PE subjects in the highest-dose cohorts.
• The company received approval from Health Canada to initiate its Phase 2 trial for early-onset PE.
• The company has $34.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
• The company has an active ATM offering with $86.2 million remaining available for issuance as of September 30, 2026.

Negatives

• The company incurred a net loss of $31.5 million for the nine months ended September 30, 2026, and has an accumulated deficit of $204.3 million.
• Net cash used in operating activities was $26.0 million for the nine months ended September 30, 2026.
• The company has substantial doubt about its ability to continue as a going concern.
• The company expects to continue incurring significant expenses and operating losses for at least the next few years.
• Slower than expected site activations and enrollment in the ReMEDy2 trial are ongoing.
• The FDA requested additional non-clinical reproductive toxicity data for the PE program, and a rat PK study is underway.
• The company may need to scale back operations or cease operations if additional financing is not obtained.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• Failure to resolve issues causing slow site activation and enrollment in the ReMEDy2 trial may result in further delays.
• The FDA's acceptance of data from clinical trials conducted outside the United States for the PE program is not guaranteed.
• The company has not generated any revenues from product sales and does not expect to for at least three to four years, if at all.
• The development, manufacturing, and marketing of pharmaceutical products require approval from regulatory agencies, which is subject to uncertainty.
• Competition for research staff and trial subjects due to other pending stroke and neurological clinical trials could impact enrollment.
• The adaptive design of the ReMEDy2 trial means the final sample size could range between 300 and 728 patients.
• The company may need to scale back operations, license rights to third parties, or cease operations if adequate funding is not available.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for at least the next few years. R&D expenses are expected to moderately increase as clinical programs advance. G&A expenses are expected to remain steady. The company anticipates needing substantial additional capital to fund its operations, clinical trials, regulatory activities, and potential commercialization.

Management Comments

• We expect to continue to incur significant expenses and operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations.
• We expect that our quarterly expenses will increase moderately relative to recent prior quarterly periods as we continue to advance our DM199 clinical development program into PE and we continue our ReMEDy2 trial, including the activation of additional study sites in the U.S. and Europe and the enrollment of additional participants in the trial.
• We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising additional capital are favorable.
• If adequate funding is not available when needed, we may be required to scale back our operations by taking actions that may include, among other things, reducing use of outside professional service providers, reducing the number of our employees or employee compensation, modifying or delaying the development of our DM199 product candidate; licensing to third parties the rights to commercialize our DM199 product candidate for PE, FGR, AIS or other indications that we would otherwise seek to pursue, or otherwise relinquishing significant rights to our technologies, future revenue streams, research programs or product candidates or granting licenses on terms that may not be favorable to us; and/or divesting assets or ceasing operations through a merger, sale, or liquidation of our Company.

Industry Context

StockSavvy.ai notes that DiaMedica Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical sector, where clinical trial success and regulatory approvals are critical determinants of value. The company's focus on rare and severe diseases like preeclampsia and acute ischemic stroke addresses significant unmet medical needs, but the path to commercialization is long and fraught with risk, as evidenced by the ongoing need for substantial financing and the inherent uncertainties in clinical development.

Comparison to Industry Standards

• Companies in the clinical-stage biopharmaceutical sector often rely heavily on equity financing to fund R&D, similar to DiaMedica's historical reliance on public and private sales of equity securities.
• The significant operating losses and accumulated deficits reported by DiaMedica are common among companies in this stage of development, where substantial investment in research and development precedes any potential revenue generation.
• The challenges in clinical trial enrollment, such as staffing shortages and competition for participants, are not unique to DiaMedica and are frequently cited by other companies in the industry.
• The need for additional financing to continue operations is a standard concern for clinical-stage biopharmaceutical companies, often leading to dilutive equity offerings or strategic partnerships.

Legal Proceedings

• The company is not currently engaged in or aware of any threatened legal actions.

Stakeholder Impact

• Shareholders may experience dilution if additional equity is issued to raise capital.
• The company's ability to continue operations impacts employees, investors, and potential future partners.
• Clinical trial participants are crucial for advancing the DM199 candidate, and their safety and well-being are paramount.
• Suppliers and service providers (e.g., CROs, manufacturing partners) are integral to the company's development process.

Next Steps

• Continue enrollment in the Phase 2/3 ReMEDy2 clinical trial for AIS.
• Await results from the interim analysis of the ReMEDy2 trial, expected by the end of Q1 2027.
• Initiate Part 1b and Part 2 of the PE/FGR Phase 2 IST by the end of 2026.
• Submit requested information to the FDA regarding the rat PK study for the PE program.
• Present detailed Part 1a results from the PE/FGR IST at an upcoming medical conference and submit for publication.
• Seek additional financing to fund ongoing operations and development activities.

Key Dates

Recommendation

While DiaMedica Therapeutics is advancing promising clinical candidates (DM199 for PE, FGR, AIS) with positive early data, the significant financial challenges, including substantial operating losses, high cash burn, and the explicit mention of 'substantial doubt about its ability to continue as a going concern,' warrant a cautious approach. The need for significant additional financing introduces considerable risk. The 'hold' recommendation reflects a balance between the potential upside from successful clinical development and the considerable financial and execution risks.

Keywords

DM199, preeclampsia, fetal growth restriction, acute ischemic stroke, clinical trials, biopharmaceutical, drug development, FDA